There was no association between the number of LNs removed and the change in upper extremity measurements or in the incidence of lymphedema. Factors associated with lymphedema included weight and body mass index. Association of lymphedema with total number of LNs excised and other clinicopathologic variables was analyzed by the Spearman rank correlation coefficient, Fisher's exact test, Wilcoxon rank sum test, and logistic regression.Īt a median follow-up of 5 years, 5% of patients had developed lymphedema. Circumferential bilateral upper extremity measurements were performed preoperatively and at 3-8 years after surgery. Six hundred patients with clinically node-negative breast cancer who underwent SLNB were prospectively studied. We hypothesized that a higher number of lymph nodes (LNs) removed during SLNB is associated with a higher risk of lymphedema. 93(5):539-46, 2006.Despite the reduced morbidity associated with sentinel lymph node biopsy (SLNB), lymphedema remains a clinically relevant complication. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Canavese G, Catturich A, Vecchio C, et al.A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Zavagno G, De Salvo GL, Scalco G, et al.Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Gill G for the SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre.for the National Surgical Adjuvant Breast and Bowel Project Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Krag DN, Anderson SJ, Julian TB, et al.Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014. Chapter 38: Axillary Dissection, in Harris JR, Lippman ME, Morrow M, Osborne CK. (blue dye, radioactive tracer or combined technique)Īccuracy in Predicting Lymph Node Status, Sensitivity %īlue dye alone, radioactive tracer or combined technique Table note: Sensitivity in the table below measures how accurately sentinel node biopsy identified lymph node status.įor example, a sensitivity of 90 percent means 90 percent of the people the sentinel node biopsy identified as having positive lymph nodes did, in fact, have cancer in their lymph nodes when checked with axillary dissection. Study selection criteria: Randomized clinical trials with at least 200 participants and meta-analyses. Learn about the strengths and weaknesses of different types of studies. Learn about lymph node status and staging. Learn about lymph node status and breast cancer prognosis (chances of survival). Learn more about sentinel node biopsy and axillary dissection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |